BILAYERED COMPOSITE TABLET FORMULATION COMPRISING ATORVASTATIN, IRBESARTAN AND MAGNESUIM CARBONATE
专利「BILAYERED COMPOSITE TABLET FORMULATION COMPRISING ATORVASTATIN, IRBESARTAN AND MAGNESUIM CARBONATE」由 HANMI PHARM. CO., LTD. 持有，当前状态为Abandoned，申请号 P/350。LaoBiz 老商通提供老挝知识产权信息检索与企业关联查询。
Patent “BILAYERED COMPOSITE TABLET FORMULATION COMPRISING ATORVASTATIN, IRBESARTAN AND MAGNESUIM CARBONATE” is held by HANMI PHARM. CO., LTD.; status: Abandoned. Search Laos IP records on LaoBiz.
P/350
图样
基础信息
- 类型
- 专利
- 申请号
P/350- 状态
- Abandoned
- 申请人
- HANMI PHARM. CO., LTD.
- 代理机构
- LAO TRADEMARK AGENCY (LAO IP AGENCY)
- 申请日期
- 2013-08-30
- 公开/公告日
- 2025-12-19
- 国际分类
- A61K 31/40 · A61K 9/20 · A61K 9/22 · A61K 9/24
- 商品 / 服务
- —
办理流程
根据当前状态动态标注-
提交申请
-
形式审查 进行中
-
实质审查
-
公开
-
授权
关联分析
LaoBiz 企业数据库联动类似专利推荐
摘要
Disclosed are a bilayered composite tablet formation comprising (a) a first layer comprising irbesartan or a pharmaceutically acceptable salt thereof; and (b) a second 5 layer comprising atorvastatin or a pharmaceutically acceptable salt thereof and magnesium carbonate (MgCOs) in a weight ratio of 1:4 to 1:5, and a method for preparing the same. Exhibiting excellent dissolution rates and bioavailability, the bilayered composite tablet formulation is useful as a therapeutic for hypertension and hypercholesterolemia. 10 [REPRESENTATIVE FIGURE]
Disclosed are a bilayered composite tablet formation comprising (a) a first layer comprising irbesartan or a pharmaceutically acceptable salt thereof; and (b) a second layer comprising atorvastatin or a pharmaceutically acceptable salt thereof and magnesium carbonate (MgCO3) in a weight ratio of 1:4 to 1:5, and a method for preparing the same. Exhibiting excellent dissolution rates and bioavailability, the bilayered composite tablet formulation is useful as a therapeutic for hypertension and hypercholesterolemia.